These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2941206)

  • 1. Ketanserin and prazosin: a comparison of antihypertensive and biochemical effects.
    Stokes GS; Mennie BA; Marwood JF
    Clin Pharmacol Ther; 1986 Jul; 40(1):56-63. PubMed ID: 2941206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moderate essential hypertension control: a double-blind crossover study between a serotonin antagonist and a post-synaptic alpha-blocker.
    Rosenthal J; Koehle W; Gruebel B; Fisher R
    J Hypertens Suppl; 1986 Apr; 4(1):S85-7. PubMed ID: 2871145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic effect of ketanserin in mild to moderate essential hypertension.
    Woittiez AJ; Wenting GJ; van den Meiracker AH; Ritsema van Eck HJ; Man in't Veld AJ; Zantvoort FA; Schalekamp MA
    Hypertension; 1986 Feb; 8(2):167-73. PubMed ID: 2935497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of ketanserin on blood pressure and biochemical parameters in treated patients with essential hypertension.
    Wing LM; Chalmers JP; West MJ; Bune AJ; Ayres B; Graham JR
    Clin Exp Hypertens A; 1984; 6(6):1107-17. PubMed ID: 6146414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute and chronic ketanserin in essential hypertension: antihypertensive mechanisms and pharmacokinetics.
    Donnelly R; Elliott HL; Meredith PA; Reid JL
    Br J Clin Pharmacol; 1987 Nov; 24(5):599-606. PubMed ID: 3325090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of ketanserin on blood pressure and biochemical parameters in patients with essential hypertension.
    Wing LM; Chalmers JP; West MJ; Bune AJ; Ayres B; Graham JR
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S164-7. PubMed ID: 2412043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-HT, alpha-adrenoceptors, and blood pressure. Effects of ketanserin in essential hypertension and autonomic insufficiency.
    Wenting GJ; Woittiez AJ; Man in't Veld AJ; Schalekamp MA
    Hypertension; 1984; 6(1):100-9. PubMed ID: 6319278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the combination of alpha- and beta-adrenoceptor blockade in hypertension.
    Stokes GS; Mennie BA; Gellatly R; Hill A
    Clin Pharmacol Ther; 1983 Nov; 34(5):576-82. PubMed ID: 6627819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ketanserin: a possible tool for studying the role of serotonin in hypertension.
    Woittiez AJ; Wenting GJ; Man in't Veld AJ; Boomsma F; Schalekamp MA
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S130-6. PubMed ID: 2412035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ketanserin: haemodynamic effects and mechanism of action.
    Schalekamp MA; Woittiez AJ; Wenting GJ; van den Meiracker AH; Man in 't Veld AJ
    J Hypertens Suppl; 1986 Apr; 4(1):S7-12. PubMed ID: 2871144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ketanserin in combination with beta-adrenergic receptor blocking agents in the treatment of essential hypertension.
    Hedner T; Persson B
    Br J Clin Pharmacol; 1984 Nov; 18(5):765-71. PubMed ID: 6150724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Felodipine versus prazosin as an addition to a beta-blocker in the treatment of essential hypertension. The Australian Multicentre Study.
    Jackson B; Morgan TO; Gibson J; Anderson A
    Drugs; 1987; 34 Suppl 3():109-19. PubMed ID: 2894971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled trial of ketanserin in hypertension.
    McGourty JC; Silas JH; Cowen KJ
    Br J Clin Pharmacol; 1985 Jul; 20(1):37-40. PubMed ID: 3161531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ketanserin in the acute management of severe hypertension.
    Murphy BF; Whitworth JA; Kincaid-Smith P
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S168-71. PubMed ID: 2412044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-adrenergic blockade makes minimal contribution to ketanserin's hypotensive effect.
    Naslund TC; Merrell WJ; Nadeau JH; Wood AJ
    Clin Pharmacol Ther; 1988 Dec; 44(6):699-703. PubMed ID: 2904312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of prazosin and verapamil in the treatment of essential hypertension.
    Elliott HL; Meredith PA; Campbell L; Reid JL
    Clin Pharmacol Ther; 1988 May; 43(5):554-60. PubMed ID: 3284690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antihypertensive therapy with ketanserin: metabolic and hemodynamic effects.
    Levinson PD; Zimlichman R; Goldstein DS; Keiser HR
    J Cardiovasc Pharmacol; 1988 Oct; 12(4):384-9. PubMed ID: 2465437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic and hemodynamic effects of antihypertensive treatment with ketanserin.
    Levinson PD; Zimlichman R; Goldstein DS; Brewer HB; Keiser HR
    Am J Hypertens; 1988 Jul; 1(3 Pt 3):245S-248S. PubMed ID: 3415801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ketanserin in hypertension. Early clinical evaluation and dose finding study of a new 5-HT2 receptor antagonist.
    Andrén L; Svensson A; Dahlöf B; Eggertsen R; Hansson L
    Acta Med Scand; 1983; 214(2):125-30. PubMed ID: 6353879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the 5-hydroxytryptamine type 2 receptor antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympatho-adrenal function in patients with essential hypertension.
    Zabludowski JR; Zoccali C; Isles CG; Murray GD; Robertson JI; Inglis GC; Fraser R; Ball SG
    Br J Clin Pharmacol; 1984 Mar; 17(3):309-16. PubMed ID: 6712863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.